Quince Therapeutics, Inc.
QNCX
$30.32
$0.822.76%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 397.49% | -10.90% | -15.15% | -9.61% | -28.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 123.21% | -14.09% | 60.61% | 32.97% | 11.91% |
| Operating Income | -123.21% | 14.09% | -60.61% | -32.97% | -11.91% |
| Income Before Tax | -371.86% | 304.05% | -191.64% | -146.18% | 42.29% |
| Income Tax Expenses | 11.94% | -11,459.57% | 44,842.86% | -453.85% | 86.11% |
| Earnings from Continuing Operations | -370.36% | 338.94% | -216.73% | -144.76% | 42.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -370.36% | 338.94% | -216.73% | -144.76% | 42.12% |
| EBIT | -123.21% | 14.09% | -60.61% | -32.97% | -11.91% |
| EBITDA | -123.59% | 14.15% | -60.48% | -33.90% | -12.07% |
| EPS Basic | 82.10% | 214.47% | -149.00% | -95.82% | 46.57% |
| Normalized Basic EPS | 95.49% | 183.10% | -154.34% | -12.78% | -74.06% |
| EPS Diluted | 82.10% | 214.47% | -149.00% | -95.82% | 46.57% |
| Normalized Diluted EPS | 95.49% | 183.10% | -154.34% | -12.78% | -74.06% |
| Average Basic Shares Outstanding | 2,527.59% | 108.74% | 27.18% | 25.02% | 8.31% |
| Average Diluted Shares Outstanding | 2,527.59% | 108.74% | 27.18% | 25.02% | 8.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |